CH669599A5 - - Google Patents

Download PDF

Info

Publication number: CH669599A5
Authority: CH; Switzerland
Prior art keywords: methyl; benzoyl; thiophene; hydroxy; formula
Prior art date: 1985-10-18

Application number

CH4154/86A

Other languages

English (en)

French (fr)

Inventor

Charles John Robert Hedgecock

David Alun Rowlands

Peter David Kennewell

Martret Odile Le

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-18

Filing date

1986-10-17

Publication date

1989-03-31

1986-10-17 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1989-03-31 Publication of CH669599A5 publication Critical patent/CH669599A5/fr

Links

-1 alkyl radical Chemical class 0.000 description 17
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 16
150000003839 salts Chemical class 0.000 description 16
238000000034 method Methods 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
WBMKDDSMYHLQTN-UHFFFAOYSA-N acetic acid;thiophene Chemical class CC(O)=O.C=1C=CSC=1 WBMKDDSMYHLQTN-UHFFFAOYSA-N 0.000 description 8
229940114079 arachidonic acid Drugs 0.000 description 8
235000021342 arachidonic acid Nutrition 0.000 description 8
125000004432 carbon atom Chemical group C* 0.000 description 8
239000003814 drug Substances 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
125000003118 aryl group Chemical group 0.000 description 6
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical group C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000000203 mixture Substances 0.000 description 6
241000700199 Cavia porcellus Species 0.000 description 5
XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 5
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 4
206010030113 Oedema Diseases 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
239000000679 carrageenan Substances 0.000 description 4
235000010418 carrageenan Nutrition 0.000 description 4
229920001525 carrageenan Polymers 0.000 description 4
229940113118 carrageenan Drugs 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 3
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
102000003820 Lipoxygenases Human genes 0.000 description 3
108090000128 Lipoxygenases Proteins 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
241000700198 Cavia Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000003710 calcium ionophore Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002329 infrared spectrum Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005980 lung dysfunction Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002904 solvent Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
125000004953 trihalomethyl group Chemical group 0.000 description 2
QOOQLKSEGVNYLA-UHFFFAOYSA-N 1-$l^{1}-oxidanylbutane Chemical compound CCCC[O] QOOQLKSEGVNYLA-UHFFFAOYSA-N 0.000 description 1
HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
229910014033 C-OH Inorganic materials 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
229910014570 C—OH Inorganic materials 0.000 description 1
WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000035567 cellular accumulation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
BYXUIKZQGOPKFR-UHFFFAOYSA-N hydron;n-propan-2-ylhydroxylamine;chloride Chemical compound Cl.CC(C)NO BYXUIKZQGOPKFR-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
230000009466 transformation Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

CH4154/86A 1985-10-18 1986-10-17 CH669599A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB858525716A GB8525716D0 (en)	1985-10-18	1985-10-18	Chemical compounds

Publications (1)

Publication Number	Publication Date
CH669599A5 true CH669599A5 (de)	1989-03-31

Family

ID=10586874

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH4154/86A CH669599A5 (de)	1985-10-18	1986-10-17

Country Status (7)

Country	Link
JP (1)	JPS6299372A (de)
CH (1)	CH669599A5 (de)
DE (1)	DE3635413A1 (de)
FR (1)	FR2588871B1 (de)
GB (2)	GB8525716D0 (de)
IT (1)	IT1214729B (de)
NL (1)	NL8602610A (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2730996B1 (fr) *	1995-02-23	1997-06-20	Adir	Nouveaux composes du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant
FR2752576B1 (fr) *	1996-08-22	1999-02-26	Adir	Nouveaux composes du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2068425B1 (de) *	1969-11-12	1973-01-12	Roussel Uclaf

1985
- 1985-10-18 GB GB858525716A patent/GB8525716D0/en active Pending
1986
- 1986-10-15 FR FR868614308A patent/FR2588871B1/fr not_active Expired - Fee Related
- 1986-10-16 JP JP61244309A patent/JPS6299372A/ja active Pending
- 1986-10-17 NL NL8602610A patent/NL8602610A/nl not_active Application Discontinuation
- 1986-10-17 CH CH4154/86A patent/CH669599A5/fr not_active IP Right Cessation
- 1986-10-17 DE DE19863635413 patent/DE3635413A1/de not_active Withdrawn
- 1986-10-17 IT IT8648565A patent/IT1214729B/it active
- 1986-10-17 GB GB8624893A patent/GB2183637B/en not_active Expired

Also Published As

Publication number	Publication date
DE3635413A1 (de)	1987-05-07
GB2183637B (en)	1989-10-25
IT8648565A0 (it)	1986-10-17
JPS6299372A (ja)	1987-05-08
IT1214729B (it)	1990-01-18
NL8602610A (nl)	1987-05-18
GB8624893D0 (en)	1986-11-19
GB2183637A (en)	1987-06-10
FR2588871B1 (fr)	1990-11-02
FR2588871A1 (fr)	1987-04-24
GB8525716D0 (en)	1985-11-20

Legal Events

Date	Code	Title	Description
1993-06-30	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
CH643546A5 (fr)	1984-06-15	Procede pour la preparation de derives d'hydantoine.
EP0624575A1 (de)	1994-11-17	Substituierte Indole und diese enthaltende Arzneimittel
EP0202157A1 (de)	1986-11-20	N-Substituierte 2-Aminothiazole, Verfahren zu ihrer Herstellung und ihre therapeutische Anwendung
EP0080941A1 (de)	1983-06-08	Pyrimidoquinoxaline, ihre Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende Zubereitungen
EP0117771B1 (de)	1987-11-11	Imino-2-pyrrolidine, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
EP0566446A1 (de)	1993-10-20	Indan-1,3-Dion und Indan-1,2,3-Trionderivate, Verfahren zu ihrer Herstellung und ihrer therapeutische Verwendung
CH652387A5 (fr)	1985-11-15	Derives d'acides phenyl aliphatique carboxyliques, leur preparation et les medicaments et compositions les renfermant.
FR2534582A1 (fr)	1984-04-20	Nouveaux derives de benzofuranne et de benzothiophene, utiles comme agents anti-hyperuricemie et anti-hypertension, et leur procede de fabrication
FR2515175A1 (fr)	1983-04-29	Nouveaux derives de l'acide 4-phenyl 4-oxo 2-butenoique, leurs sels, leur preparation, leur application comme medicaments et les compositions les renfermant
CH669599A5 (de)	1989-03-31
EP0533573B1 (de)	1996-12-04	Derivate des 3-Cyclo-alkylpropen-2-amide, deren Tautomere und Salze und ihre Verwendung als entzündungshemmende Wirkstoffe
WO1990003972A1 (fr)	1990-04-19	Derives de methyl-4 ((phenyl-4 piperazinyl-1)-2 ethyl)-5 thiazole
BE779775A (fr)	1972-08-24	Derives de l'uree, procede pour les preparer et leurs applications
EP0196943B1 (de)	1990-01-24	8-Thiotetrahydrochinoleinderivate und deren Salze
EP0002401B1 (de)	1980-12-10	Naphtalen-Derivate, Verfahren zu deren Herstellung und deren Verwendung in der Therapeutik
CH654289A5 (fr)	1986-02-14	Medicaments constitues par certains derives de l'acide 4-phenyl 4-oxo 2-butenoique et compositions les renfermant.
FR2481270A1 (fr)	1981-10-30	Nouveaux derives substitues de l'acide 4-phenyl 4-oxo 2-hydroxy butanoique, procede pour leur preparation et applications comme medicaments
EP0183584B1 (de)	1989-12-06	Esterderivate von 2-alpha-hydroxy-substituierter 4-Hydroxy-3-chinolincarbonsäure, ihre Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende Zubereitungen
EP0076713B1 (de)	1986-01-08	Aminomethyl 1H-Indole 4-Methanol Derivate und ihre Salze, Verfahren und Zwischenprodukte zu ihren Herstellung, Verwendung als Heilmittel und Zusammenstellungen die sie enthalten
FR2677477A1 (fr)	1992-12-11	Nouveaux derives de l'oxazole leur preparation, leur utilisation et les compositions pharmaceutiques qui les contiennent.
EP0347305B1 (de)	1993-05-12	[(Aryl-4-piperazinyl-1)-2-ethoxy]-3p-cymole, die ortho-, meta-, para-monosubstituierten oder disubstituierten Derivate, das Verfahren zu deren Herstellung und die als aktives Prinzip diese Verbindungen enthaltenden Arzneimittel
EP0275221B1 (de)	1991-04-17	N-(1H-indol-4-yl)-Benzamidderivate, ihre Salze und deren Anwendung als Heilmittel und Zusammenstellungen, die sie enthalten
EP0211759B1 (de)	1991-04-17	Pyrimido[2,1-b]benzothiazolderivate und ihre Salze, Verfahren zu ihrer Herstellung, Verwendung als Arzneimittel und die sie enthaltenden Zubereitungen
CH627750A5 (fr)	1982-01-29	Derives de la benzophenone, procede de preparation et compositions pharmaceutiques.
FR2539127A1 (fr)	1984-07-13	Nouveaux derives du 4h-1,2,4-triazole, leur procede de preparation et leur application comme medicaments